Mary Weiser-Evans
Concepts (424)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocytes, Smooth Muscle | 21 | 2023 | 257 | 4.090 |
Why?
| PTEN Phosphohydrolase | 13 | 2020 | 157 | 3.810 |
Why?
| Muscle, Smooth, Vascular | 25 | 2023 | 441 | 3.700 |
Why?
| Vascular Remodeling | 8 | 2022 | 189 | 2.670 |
Why?
| Atherosclerosis | 4 | 2023 | 402 | 2.200 |
Why?
| Plaque, Atherosclerotic | 2 | 2023 | 53 | 1.630 |
Why?
| Adventitia | 2 | 2022 | 40 | 1.290 |
Why?
| Kruppel-Like Transcription Factors | 2 | 2020 | 65 | 1.180 |
Why?
| Stem Cells | 6 | 2023 | 574 | 1.100 |
Why?
| Fibrosis | 12 | 2023 | 526 | 1.070 |
Why?
| Lung Neoplasms | 19 | 2023 | 2342 | 1.020 |
Why?
| Vascular System Injuries | 3 | 2023 | 73 | 0.970 |
Why?
| Mice | 43 | 2024 | 16973 | 0.920 |
Why?
| Myofibroblasts | 2 | 2023 | 120 | 0.910 |
Why?
| Cell Proliferation | 18 | 2021 | 2367 | 0.890 |
Why?
| Neointima | 4 | 2022 | 15 | 0.830 |
Why?
| Hypercholesterolemia | 1 | 2023 | 101 | 0.790 |
Why?
| Tunica Intima | 5 | 2010 | 84 | 0.780 |
Why?
| Animals | 63 | 2024 | 35334 | 0.780 |
Why?
| Spinocerebellar Ataxias | 1 | 2022 | 6 | 0.780 |
Why?
| Galectin 3 | 1 | 2022 | 20 | 0.780 |
Why?
| Cell Differentiation | 10 | 2023 | 1895 | 0.730 |
Why?
| Heart-Assist Devices | 4 | 2022 | 538 | 0.720 |
Why?
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 17 | 0.680 |
Why?
| Serum Response Factor | 3 | 2016 | 32 | 0.650 |
Why?
| Carotid Artery Injuries | 5 | 2010 | 41 | 0.640 |
Why?
| Mice, Knockout | 16 | 2024 | 2887 | 0.640 |
Why?
| Chemokine CXCL12 | 2 | 2011 | 79 | 0.630 |
Why?
| Coronary Restenosis | 1 | 2019 | 21 | 0.630 |
Why?
| Coronary Vessels | 2 | 2018 | 239 | 0.630 |
Why?
| Cyclin D1 | 1 | 2019 | 62 | 0.630 |
Why?
| Mice, Inbred C57BL | 22 | 2024 | 5468 | 0.620 |
Why?
| High-Throughput Screening Assays | 1 | 2020 | 139 | 0.610 |
Why?
| Arteries | 4 | 2022 | 266 | 0.550 |
Why?
| Vascular Diseases | 1 | 2019 | 240 | 0.540 |
Why?
| Tumor Microenvironment | 8 | 2021 | 627 | 0.530 |
Why?
| Rats | 20 | 2019 | 5470 | 0.520 |
Why?
| Cells, Cultured | 18 | 2024 | 4087 | 0.520 |
Why?
| Heparan Sulfate Proteoglycans | 4 | 2003 | 22 | 0.510 |
Why?
| Mice, Transgenic | 9 | 2020 | 2135 | 0.500 |
Why?
| PPAR gamma | 7 | 2019 | 183 | 0.480 |
Why?
| Gene Expression Regulation | 6 | 2024 | 2544 | 0.480 |
Why?
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1050 | 0.470 |
Why?
| Disease Models, Animal | 17 | 2024 | 4073 | 0.450 |
Why?
| Cell Division | 8 | 2004 | 787 | 0.440 |
Why?
| Hypertension, Pulmonary | 5 | 2023 | 1891 | 0.430 |
Why?
| Acute Kidney Injury | 5 | 2023 | 789 | 0.420 |
Why?
| Signal Transduction | 18 | 2019 | 4916 | 0.420 |
Why?
| Hypertension | 1 | 2022 | 1235 | 0.420 |
Why?
| Hyperplasia | 5 | 2020 | 175 | 0.410 |
Why?
| MicroRNAs | 2 | 2017 | 677 | 0.410 |
Why?
| Protein Kinases | 4 | 2014 | 314 | 0.390 |
Why?
| Transforming Growth Factor beta1 | 3 | 2023 | 158 | 0.370 |
Why?
| Bone Marrow Cells | 2 | 2011 | 302 | 0.360 |
Why?
| Ureteral Obstruction | 3 | 2021 | 62 | 0.350 |
Why?
| Cell Movement | 5 | 2012 | 942 | 0.340 |
Why?
| Kidney | 6 | 2021 | 1382 | 0.340 |
Why?
| Muscle, Smooth | 2 | 2023 | 159 | 0.330 |
Why?
| Macrophages | 4 | 2021 | 1486 | 0.320 |
Why?
| Autocrine Communication | 2 | 2014 | 41 | 0.320 |
Why?
| Cell Dedifferentiation | 3 | 2016 | 30 | 0.310 |
Why?
| Phospholipases A2, Cytosolic | 1 | 2009 | 7 | 0.310 |
Why?
| Angiotensin II | 3 | 2021 | 95 | 0.310 |
Why?
| Group IV Phospholipases A2 | 3 | 2017 | 47 | 0.300 |
Why?
| Platelet-Derived Growth Factor | 4 | 2020 | 89 | 0.300 |
Why?
| Cisplatin | 3 | 2020 | 298 | 0.290 |
Why?
| Male | 26 | 2024 | 63586 | 0.280 |
Why?
| Carcinoma, Lewis Lung | 2 | 2019 | 13 | 0.280 |
Why?
| Proteins | 2 | 2006 | 944 | 0.280 |
Why?
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 35 | 0.280 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 4 | 2019 | 34 | 0.270 |
Why?
| Proto-Oncogene Proteins c-akt | 7 | 2014 | 427 | 0.270 |
Why?
| Heart Failure | 4 | 2023 | 2143 | 0.270 |
Why?
| Nuclear Proteins | 2 | 2023 | 659 | 0.270 |
Why?
| Rats, Sprague-Dawley | 9 | 2016 | 2393 | 0.270 |
Why?
| Hypoxia | 2 | 2013 | 1081 | 0.260 |
Why?
| Actins | 3 | 2018 | 406 | 0.260 |
Why?
| TOR Serine-Threonine Kinases | 5 | 2014 | 393 | 0.260 |
Why?
| Proto-Oncogene Proteins | 3 | 2004 | 632 | 0.260 |
Why?
| Acetyltransferases | 1 | 2006 | 21 | 0.250 |
Why?
| Endothelial Cells | 2 | 2022 | 739 | 0.250 |
Why?
| Adenocarcinoma | 5 | 2017 | 889 | 0.240 |
Why?
| Protein-Tyrosine Kinases | 3 | 2003 | 431 | 0.240 |
Why?
| Inflammation | 4 | 2023 | 2741 | 0.240 |
Why?
| Polycystic Kidney, Autosomal Dominant | 2 | 2019 | 254 | 0.240 |
Why?
| RNA Interference | 5 | 2014 | 450 | 0.240 |
Why?
| Embryonic Development | 1 | 2006 | 113 | 0.240 |
Why?
| Fibromuscular Dysplasia | 1 | 2024 | 7 | 0.230 |
Why?
| Phosphatidylinositol 3-Kinases | 4 | 2010 | 353 | 0.230 |
Why?
| Myeloid Cells | 2 | 2019 | 141 | 0.230 |
Why?
| Gene Expression | 3 | 2014 | 1461 | 0.220 |
Why?
| Humans | 33 | 2024 | 129527 | 0.220 |
Why?
| Phenotype | 10 | 2024 | 3058 | 0.220 |
Why?
| Ribosomal Protein S6 | 1 | 2004 | 15 | 0.220 |
Why?
| Corn Oil | 1 | 2023 | 5 | 0.220 |
Why?
| Inflammation Mediators | 2 | 2021 | 503 | 0.220 |
Why?
| Receptors, LDL | 1 | 2023 | 46 | 0.210 |
Why?
| Azotemia | 1 | 2023 | 7 | 0.210 |
Why?
| Proprotein Convertase 9 | 1 | 2023 | 68 | 0.210 |
Why?
| Phosphorylation | 6 | 2019 | 1714 | 0.200 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2004 | 164 | 0.200 |
Why?
| Lipoxygenase Inhibitors | 2 | 2021 | 38 | 0.200 |
Why?
| Disease Progression | 7 | 2019 | 2628 | 0.200 |
Why?
| Rejuvenation | 1 | 2022 | 18 | 0.200 |
Why?
| Fibroblasts | 2 | 2024 | 943 | 0.190 |
Why?
| Gene Regulatory Networks | 1 | 2024 | 280 | 0.190 |
Why?
| Extracellular Matrix | 4 | 2021 | 506 | 0.190 |
Why?
| Polycystic Kidney Diseases | 2 | 2019 | 68 | 0.190 |
Why?
| Programmed Cell Death 1 Receptor | 3 | 2020 | 232 | 0.190 |
Why?
| Aortic Valve Insufficiency | 1 | 2022 | 46 | 0.190 |
Why?
| Arachidonate 12-Lipoxygenase | 1 | 2021 | 17 | 0.190 |
Why?
| Arachidonate 15-Lipoxygenase | 1 | 2021 | 23 | 0.190 |
Why?
| Nephritis | 1 | 2021 | 22 | 0.190 |
Why?
| Cytokines | 4 | 2021 | 2018 | 0.190 |
Why?
| DNA Helicases | 1 | 2023 | 146 | 0.180 |
Why?
| Assisted Circulation | 1 | 2021 | 26 | 0.180 |
Why?
| Zebrafish | 1 | 2006 | 460 | 0.180 |
Why?
| Cholesterol | 1 | 2023 | 399 | 0.180 |
Why?
| Adaptive Immunity | 2 | 2023 | 161 | 0.180 |
Why?
| Cell Line, Tumor | 9 | 2019 | 3181 | 0.180 |
Why?
| Dual-Specificity Phosphatases | 1 | 2021 | 11 | 0.180 |
Why?
| Transcription Factors | 4 | 2023 | 1642 | 0.180 |
Why?
| Metformin | 2 | 2023 | 316 | 0.180 |
Why?
| Promoter Regions, Genetic | 5 | 2020 | 1211 | 0.180 |
Why?
| Protein Kinase Inhibitors | 3 | 2023 | 885 | 0.180 |
Why?
| Female | 17 | 2024 | 68650 | 0.180 |
Why?
| Hypertrophy, Right Ventricular | 1 | 2021 | 144 | 0.170 |
Why?
| Ventricular Dysfunction, Right | 1 | 2023 | 231 | 0.170 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2017 | 1058 | 0.170 |
Why?
| Blotting, Western | 3 | 2019 | 1199 | 0.170 |
Why?
| Homeostasis | 2 | 2022 | 605 | 0.170 |
Why?
| Aortic Diseases | 1 | 2021 | 114 | 0.170 |
Why?
| Jugular Veins | 1 | 2020 | 41 | 0.170 |
Why?
| Antineoplastic Agents, Immunological | 2 | 2019 | 181 | 0.170 |
Why?
| Intestines | 1 | 2023 | 350 | 0.160 |
Why?
| Myocytes, Cardiac | 2 | 2014 | 492 | 0.160 |
Why?
| Wound Healing | 1 | 2022 | 308 | 0.160 |
Why?
| Crohn Disease | 1 | 2023 | 217 | 0.160 |
Why?
| Arachidonate 5-Lipoxygenase | 2 | 2019 | 42 | 0.160 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 131 | 0.160 |
Why?
| GATA4 Transcription Factor | 1 | 2019 | 18 | 0.160 |
Why?
| Chromatin | 1 | 2023 | 478 | 0.160 |
Why?
| Kidney Tubules | 2 | 2019 | 114 | 0.160 |
Why?
| Neovascularization, Physiologic | 1 | 2000 | 173 | 0.160 |
Why?
| Azacitidine | 1 | 2020 | 137 | 0.160 |
Why?
| Wnt Signaling Pathway | 1 | 2020 | 169 | 0.150 |
Why?
| Pulmonary Artery | 3 | 2021 | 1075 | 0.150 |
Why?
| Catheterization | 4 | 2004 | 176 | 0.150 |
Why?
| AMP-Activated Protein Kinases | 2 | 2023 | 190 | 0.150 |
Why?
| Metabolome | 1 | 2021 | 338 | 0.150 |
Why?
| Bone Marrow | 2 | 2017 | 272 | 0.150 |
Why?
| Epigenesis, Genetic | 1 | 2023 | 617 | 0.150 |
Why?
| Flow Cytometry | 2 | 2019 | 1158 | 0.150 |
Why?
| Histocompatibility Antigens Class II | 1 | 2020 | 363 | 0.150 |
Why?
| Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.150 |
Why?
| Sirolimus | 2 | 2014 | 270 | 0.140 |
Why?
| Heart Ventricles | 2 | 2021 | 778 | 0.140 |
Why?
| Skin | 1 | 2022 | 724 | 0.140 |
Why?
| Interleukin-33 | 1 | 2017 | 48 | 0.140 |
Why?
| Trans-Activators | 1 | 2020 | 392 | 0.140 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2019 | 201 | 0.140 |
Why?
| Receptors, Complement | 1 | 2017 | 122 | 0.140 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 398 | 0.130 |
Why?
| Epithelial Cells | 3 | 2019 | 1061 | 0.130 |
Why?
| Immunotherapy | 2 | 2018 | 596 | 0.130 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2021 | 855 | 0.130 |
Why?
| Energy Metabolism | 1 | 2021 | 864 | 0.120 |
Why?
| Ventricular Remodeling | 2 | 2023 | 256 | 0.120 |
Why?
| Cell Cycle Proteins | 1 | 2019 | 583 | 0.120 |
Why?
| Gene Deletion | 2 | 2014 | 379 | 0.120 |
Why?
| Interferon-gamma | 1 | 2019 | 773 | 0.120 |
Why?
| Dinoprostone | 3 | 2016 | 187 | 0.120 |
Why?
| B7-H1 Antigen | 1 | 2017 | 198 | 0.120 |
Why?
| Autophagy | 2 | 2014 | 265 | 0.120 |
Why?
| Focal Adhesion Kinase 1 | 3 | 2003 | 31 | 0.120 |
Why?
| NF-kappa B | 2 | 2010 | 666 | 0.120 |
Why?
| Intracellular Signaling Peptides and Proteins | 3 | 2019 | 443 | 0.120 |
Why?
| Aorta | 3 | 2004 | 407 | 0.110 |
Why?
| Interleukin-6 | 3 | 2023 | 724 | 0.110 |
Why?
| Retinoid X Receptors | 1 | 2014 | 39 | 0.110 |
Why?
| Complement Activation | 1 | 2017 | 385 | 0.110 |
Why?
| Pleural Neoplasms | 1 | 2014 | 24 | 0.110 |
Why?
| Culture Media, Serum-Free | 2 | 2004 | 48 | 0.110 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 51 | 0.110 |
Why?
| Mesothelioma | 1 | 2014 | 38 | 0.110 |
Why?
| Kidney Diseases | 1 | 2017 | 382 | 0.110 |
Why?
| Gene Amplification | 1 | 2014 | 103 | 0.110 |
Why?
| Leukotrienes | 1 | 2013 | 37 | 0.110 |
Why?
| Paracrine Communication | 1 | 2014 | 59 | 0.110 |
Why?
| Eicosanoids | 1 | 2013 | 57 | 0.110 |
Why?
| Oligonucleotides, Antisense | 2 | 2004 | 111 | 0.110 |
Why?
| RNA | 1 | 2019 | 876 | 0.100 |
Why?
| Myocardial Contraction | 1 | 2014 | 334 | 0.100 |
Why?
| Monocytes | 1 | 2016 | 554 | 0.100 |
Why?
| Renal Insufficiency, Chronic | 1 | 2019 | 566 | 0.100 |
Why?
| Iloprost | 2 | 2010 | 45 | 0.100 |
Why?
| Macrophage Activation | 1 | 2014 | 189 | 0.100 |
Why?
| Macrophages, Alveolar | 1 | 2016 | 389 | 0.100 |
Why?
| Tumor Burden | 3 | 2020 | 287 | 0.100 |
Why?
| Cardiomyopathy, Hypertrophic | 1 | 2014 | 131 | 0.100 |
Why?
| MAP Kinase Signaling System | 3 | 2021 | 312 | 0.100 |
Why?
| Up-Regulation | 2 | 2008 | 832 | 0.100 |
Why?
| Immunohistochemistry | 4 | 2021 | 1684 | 0.090 |
Why?
| Endothelium, Vascular | 1 | 2018 | 895 | 0.090 |
Why?
| Heparitin Sulfate | 2 | 2003 | 42 | 0.090 |
Why?
| Lipocalin-2 | 2 | 2023 | 76 | 0.090 |
Why?
| Transforming Growth Factor beta | 1 | 2014 | 462 | 0.090 |
Why?
| Splenectomy | 1 | 2011 | 58 | 0.090 |
Why?
| Protein Processing, Post-Translational | 2 | 2004 | 456 | 0.090 |
Why?
| T-Lymphocytes | 2 | 2017 | 1935 | 0.090 |
Why?
| Cyclooxygenase 2 | 2 | 2010 | 174 | 0.090 |
Why?
| Histone Deacetylases | 1 | 2012 | 211 | 0.080 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2012 | 208 | 0.080 |
Why?
| Green Fluorescent Proteins | 1 | 2011 | 390 | 0.080 |
Why?
| Frizzled Receptors | 1 | 2010 | 23 | 0.080 |
Why?
| Case-Control Studies | 3 | 2024 | 3383 | 0.080 |
Why?
| p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 277 | 0.080 |
Why?
| RNA, Small Interfering | 2 | 2010 | 590 | 0.080 |
Why?
| Receptors, Epoprostenol | 1 | 2008 | 6 | 0.080 |
Why?
| TRPP Cation Channels | 2 | 2019 | 79 | 0.080 |
Why?
| Reperfusion Injury | 1 | 2011 | 272 | 0.080 |
Why?
| Lung Injury | 1 | 2011 | 211 | 0.070 |
Why?
| Antineoplastic Agents | 2 | 2017 | 2044 | 0.070 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2010 | 206 | 0.070 |
Why?
| Severity of Illness Index | 2 | 2013 | 2734 | 0.070 |
Why?
| Adenosine Triphosphate | 2 | 2014 | 475 | 0.070 |
Why?
| Glycoproteins | 1 | 2010 | 338 | 0.070 |
Why?
| Hematopoietic Stem Cells | 1 | 2011 | 382 | 0.070 |
Why?
| Epoprostenol | 1 | 2008 | 136 | 0.070 |
Why?
| Receptors, CXCR4 | 1 | 2008 | 83 | 0.070 |
Why?
| Cell Transformation, Neoplastic | 1 | 2010 | 318 | 0.070 |
Why?
| Culture Media, Conditioned | 2 | 2014 | 109 | 0.070 |
Why?
| Gene Silencing | 2 | 2019 | 189 | 0.070 |
Why?
| Biomarkers | 4 | 2023 | 3968 | 0.070 |
Why?
| Middle Aged | 4 | 2024 | 31087 | 0.060 |
Why?
| Neoplasm Metastasis | 1 | 2009 | 609 | 0.060 |
Why?
| RNA, Messenger | 5 | 2010 | 2697 | 0.060 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 275 | 0.060 |
Why?
| Antihypertensive Agents | 1 | 2010 | 484 | 0.060 |
Why?
| Apoptosis | 3 | 2020 | 2488 | 0.060 |
Why?
| Mitogens | 1 | 2005 | 61 | 0.060 |
Why?
| Neoplasm Transplantation | 2 | 2016 | 253 | 0.060 |
Why?
| Acetylation | 1 | 2006 | 243 | 0.060 |
Why?
| Mutation | 3 | 2023 | 3702 | 0.060 |
Why?
| Animals, Genetically Modified | 1 | 2006 | 231 | 0.060 |
Why?
| Pregnancy | 2 | 2016 | 6412 | 0.060 |
Why?
| Protein Subunits | 1 | 2006 | 233 | 0.060 |
Why?
| Gene Knockout Techniques | 2 | 2015 | 109 | 0.060 |
Why?
| Enzyme Inhibitors | 2 | 2007 | 825 | 0.060 |
Why?
| Cell Size | 2 | 2005 | 89 | 0.060 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 169 | 0.060 |
Why?
| Chromones | 1 | 2004 | 44 | 0.050 |
Why?
| Gene Expression Profiling | 3 | 2016 | 1684 | 0.050 |
Why?
| Basement Membrane | 1 | 2003 | 32 | 0.050 |
Why?
| Androstadienes | 1 | 2004 | 106 | 0.050 |
Why?
| Acute-Phase Reaction | 1 | 2023 | 40 | 0.050 |
Why?
| Embryo, Mammalian | 2 | 2003 | 224 | 0.050 |
Why?
| Furosemide | 1 | 2023 | 37 | 0.050 |
Why?
| Tenascin | 1 | 2003 | 14 | 0.050 |
Why?
| Glycosaminoglycans | 1 | 2003 | 84 | 0.050 |
Why?
| Peroxidases | 1 | 2003 | 34 | 0.050 |
Why?
| Morpholines | 1 | 2004 | 122 | 0.050 |
Why?
| Peroxidase | 2 | 2015 | 175 | 0.050 |
Why?
| Fibronectins | 1 | 2003 | 126 | 0.050 |
Why?
| Murinae | 1 | 2022 | 2 | 0.050 |
Why?
| Transfection | 3 | 2014 | 916 | 0.050 |
Why?
| Adult | 3 | 2024 | 35505 | 0.050 |
Why?
| Ileum | 1 | 2023 | 116 | 0.050 |
Why?
| Metalloproteases | 1 | 2022 | 43 | 0.050 |
Why?
| Coculture Techniques | 2 | 2014 | 224 | 0.050 |
Why?
| Aniline Compounds | 1 | 2023 | 97 | 0.050 |
Why?
| Cadherins | 2 | 2016 | 187 | 0.050 |
Why?
| Aged | 2 | 2018 | 22063 | 0.050 |
Why?
| DNA Replication | 1 | 2003 | 225 | 0.050 |
Why?
| Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.050 |
Why?
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.050 |
Why?
| ADAMTS4 Protein | 1 | 2021 | 16 | 0.050 |
Why?
| Cell Line | 2 | 2018 | 2774 | 0.050 |
Why?
| Aorta, Thoracic | 1 | 2003 | 263 | 0.040 |
Why?
| Neoplasms | 1 | 2015 | 2450 | 0.040 |
Why?
| Cellular Microenvironment | 1 | 2021 | 83 | 0.040 |
Why?
| Ventricular Function, Right | 1 | 2023 | 276 | 0.040 |
Why?
| Recombinant Fusion Proteins | 1 | 2003 | 650 | 0.040 |
Why?
| Vasoconstrictor Agents | 1 | 2021 | 127 | 0.040 |
Why?
| Major Histocompatibility Complex | 1 | 2021 | 229 | 0.040 |
Why?
| Blood Urea Nitrogen | 1 | 2020 | 53 | 0.040 |
Why?
| Butadienes | 1 | 2020 | 36 | 0.040 |
Why?
| Contractile Proteins | 1 | 2000 | 14 | 0.040 |
Why?
| Leukocytes | 1 | 2021 | 304 | 0.040 |
Why?
| Liver | 2 | 2023 | 1836 | 0.040 |
Why?
| Cell Fusion | 1 | 2000 | 51 | 0.040 |
Why?
| Thiazolidinediones | 2 | 2011 | 137 | 0.040 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 53 | 0.040 |
Why?
| NADH, NADPH Oxidoreductases | 1 | 2019 | 17 | 0.040 |
Why?
| Growth Substances | 1 | 2000 | 147 | 0.040 |
Why?
| Enzyme Activation | 2 | 2014 | 806 | 0.040 |
Why?
| Genes, Tumor Suppressor | 1 | 2000 | 84 | 0.040 |
Why?
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2023 | 711 | 0.040 |
Why?
| Cloning, Molecular | 1 | 2000 | 524 | 0.040 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2003 | 383 | 0.040 |
Why?
| ErbB Receptors | 1 | 2023 | 605 | 0.040 |
Why?
| Chemokine CXCL9 | 1 | 2019 | 27 | 0.040 |
Why?
| Pyrimidinones | 1 | 2020 | 102 | 0.040 |
Why?
| Mesoderm | 1 | 2020 | 138 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2021 | 426 | 0.040 |
Why?
| Nitriles | 1 | 2020 | 169 | 0.040 |
Why?
| Tropoelastin | 1 | 1999 | 11 | 0.040 |
Why?
| Receptors, Leukotriene | 1 | 2019 | 13 | 0.040 |
Why?
| Receptors, Transforming Growth Factor beta | 1 | 2019 | 56 | 0.040 |
Why?
| Aortic Valve | 1 | 2022 | 348 | 0.040 |
Why?
| Luciferases | 2 | 2010 | 147 | 0.040 |
Why?
| Pyridones | 1 | 2020 | 158 | 0.040 |
Why?
| Proteoglycans | 1 | 1999 | 107 | 0.040 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2003 | 819 | 0.040 |
Why?
| Drug Resistance, Neoplasm | 1 | 2023 | 751 | 0.040 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 259 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 952 | 0.040 |
Why?
| Antibodies, Blocking | 1 | 2017 | 33 | 0.030 |
Why?
| Complement C3d | 1 | 2017 | 65 | 0.030 |
Why?
| Tumor Cells, Cultured | 2 | 2010 | 931 | 0.030 |
Why?
| Neoplasm Proteins | 1 | 2020 | 417 | 0.030 |
Why?
| Complement C3 | 1 | 2017 | 208 | 0.030 |
Why?
| Myocardial Ischemia | 1 | 2018 | 259 | 0.030 |
Why?
| Arachidonic Acid | 1 | 2016 | 115 | 0.030 |
Why?
| Immunoglobulin M | 1 | 2017 | 276 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 391 | 0.030 |
Why?
| Immunocompetence | 1 | 2016 | 42 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2024 | 2271 | 0.030 |
Why?
| Oncogene Proteins, Fusion | 1 | 2017 | 200 | 0.030 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 160 | 0.030 |
Why?
| Lymphocyte Depletion | 1 | 2015 | 134 | 0.030 |
Why?
| Organ Culture Techniques | 2 | 2007 | 155 | 0.030 |
Why?
| Kidney Function Tests | 1 | 2015 | 152 | 0.030 |
Why?
| Homozygote | 1 | 2015 | 195 | 0.030 |
Why?
| Time Factors | 2 | 2017 | 6530 | 0.030 |
Why?
| Chemokines | 1 | 2016 | 227 | 0.030 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2017 | 804 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 328 | 0.030 |
Why?
| Caspase 3 | 1 | 2015 | 244 | 0.030 |
Why?
| Ventricular Function, Left | 1 | 2018 | 529 | 0.030 |
Why?
| Tetrahydronaphthalenes | 1 | 2014 | 29 | 0.030 |
Why?
| Proto-Oncogene Proteins c-sis | 2 | 2005 | 35 | 0.030 |
Why?
| Intracellular Space | 1 | 2014 | 69 | 0.030 |
Why?
| Heart | 1 | 2018 | 643 | 0.030 |
Why?
| Carcinogenesis | 1 | 2016 | 211 | 0.030 |
Why?
| Macrophage Colony-Stimulating Factor | 1 | 2014 | 17 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2015 | 481 | 0.030 |
Why?
| Chemokine CCL2 | 1 | 2014 | 117 | 0.030 |
Why?
| Pyridazines | 1 | 2014 | 54 | 0.030 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2014 | 84 | 0.030 |
Why?
| Ventricular Myosins | 1 | 2014 | 34 | 0.030 |
Why?
| Clone Cells | 1 | 2014 | 262 | 0.030 |
Why?
| Superoxides | 1 | 2014 | 201 | 0.030 |
Why?
| Microfilament Proteins | 1 | 2014 | 127 | 0.030 |
Why?
| Cardiomegaly | 1 | 2014 | 170 | 0.030 |
Why?
| Calcium-Binding Proteins | 1 | 2014 | 212 | 0.030 |
Why?
| Imidazoles | 1 | 2014 | 235 | 0.030 |
Why?
| Integrases | 1 | 2014 | 117 | 0.030 |
Why?
| Femoral Artery | 1 | 2014 | 174 | 0.020 |
Why?
| Metabolic Networks and Pathways | 1 | 2013 | 177 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2022 | 1636 | 0.020 |
Why?
| Lipid Metabolism | 1 | 2016 | 500 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2019 | 1159 | 0.020 |
Why?
| Mice, Nude | 1 | 2014 | 677 | 0.020 |
Why?
| Hypoglycemic Agents | 2 | 2011 | 1219 | 0.020 |
Why?
| Cardiac Surgical Procedures | 1 | 2017 | 509 | 0.020 |
Why?
| Capillary Leak Syndrome | 1 | 2011 | 12 | 0.020 |
Why?
| Chemokine CXCL1 | 1 | 2011 | 72 | 0.020 |
Why?
| Vasoconstriction | 1 | 2012 | 199 | 0.020 |
Why?
| Benzamides | 1 | 2012 | 203 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 376 | 0.020 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2011 | 177 | 0.020 |
Why?
| Cell Lineage | 1 | 2012 | 332 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2017 | 1366 | 0.020 |
Why?
| Snail Family Transcription Factors | 1 | 2010 | 18 | 0.020 |
Why?
| Regional Blood Flow | 1 | 2012 | 464 | 0.020 |
Why?
| Models, Animal | 1 | 2011 | 375 | 0.020 |
Why?
| Glycogen Synthase Kinase 3 | 1 | 2010 | 81 | 0.020 |
Why?
| Matrix Metalloproteinases | 1 | 2010 | 91 | 0.020 |
Why?
| Interleukin-10 | 1 | 2011 | 298 | 0.020 |
Why?
| Spleen | 1 | 2011 | 508 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2011 | 368 | 0.020 |
Why?
| Myocardium | 1 | 2014 | 981 | 0.020 |
Why?
| Intramolecular Oxidoreductases | 1 | 2008 | 68 | 0.020 |
Why?
| Cell Adhesion | 1 | 2010 | 454 | 0.020 |
Why?
| Pyrimidines | 1 | 2012 | 458 | 0.020 |
Why?
| Metabolomics | 1 | 2013 | 652 | 0.020 |
Why?
| Pyridines | 1 | 2012 | 478 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2008 | 171 | 0.020 |
Why?
| Sulindac | 1 | 2007 | 15 | 0.020 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 47 | 0.020 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2008 | 151 | 0.020 |
Why?
| Prognosis | 1 | 2016 | 3772 | 0.020 |
Why?
| Culture Media | 1 | 2007 | 162 | 0.020 |
Why?
| Mice, Mutant Strains | 1 | 2007 | 298 | 0.020 |
Why?
| Transgenes | 1 | 2007 | 177 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2007 | 170 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2011 | 1203 | 0.020 |
Why?
| Respiratory Mucosa | 1 | 2008 | 310 | 0.020 |
Why?
| Genes, jun | 1 | 2005 | 9 | 0.020 |
Why?
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2005 | 6 | 0.020 |
Why?
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 37 | 0.020 |
Why?
| Heterotrimeric GTP-Binding Proteins | 1 | 2005 | 14 | 0.010 |
Why?
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2005 | 19 | 0.010 |
Why?
| Blood Pressure | 1 | 2012 | 1735 | 0.010 |
Why?
| Genetic Markers | 1 | 2005 | 334 | 0.010 |
Why?
| Genotype | 1 | 2008 | 1827 | 0.010 |
Why?
| Transcriptional Activation | 1 | 2005 | 366 | 0.010 |
Why?
| Heparin Lyase | 1 | 2003 | 5 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2007 | 2013 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 754 | 0.010 |
Why?
| Cattle | 1 | 2004 | 959 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2003 | 842 | 0.010 |
Why?
| Binding Sites | 1 | 2003 | 1250 | 0.010 |
Why?
| Homeodomain Proteins | 1 | 2003 | 493 | 0.010 |
Why?
| Bromodeoxyuridine | 1 | 1999 | 78 | 0.010 |
Why?
| In Situ Hybridization | 1 | 1999 | 296 | 0.010 |
Why?
| Tissue Distribution | 1 | 1999 | 315 | 0.010 |
Why?
| Muscle Development | 1 | 1999 | 108 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 1717 | 0.010 |
Why?
| DNA-Binding Proteins | 1 | 2003 | 1438 | 0.010 |
Why?
| Gestational Age | 1 | 1999 | 875 | 0.010 |
Why?
| DNA | 1 | 1999 | 1400 | 0.010 |
Why?
|
|
Weiser-Evans's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|